Barbara Blouw
YOU?
Author Swipe
View article: BIOM-04 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123)
BIOM-04 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123) Open
Leptomeningeal metastases (LM) or the presence of cancer cells in the cerebrospinal fluid (CSF)/pia remains a challenging disease to diagnosis and treat. Current standard of care methods to diagnose or assess treatment response of LM (Clin…
View article: CTSI-06 PHASE 1 DOSE ESCALATION OF RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL (REYOBIQ) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): CLINICAL STUDY RESULTS FOR SAFETY AND EFFICACY
CTSI-06 PHASE 1 DOSE ESCALATION OF RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL (REYOBIQ) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): CLINICAL STUDY RESULTS FOR SAFETY AND EFFICACY Open
Leptomeningeal disease (LMD) is a devastating cancer complication with poor survival. Rhenium obisbemeda (Reyobiq) is a liposomal encapsulated radiopharmaceutical evaluated in a phase 1 dose escalation study (ReSPECT-LM) for patients with …
View article: BIOM-03 THE ONCOGENIC FLIP IN PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE (LMD): LONGITUDINAL DETECTION IN CEREBROSPINAL FLUID TUMOR CELLS (CSF-TCS) REVEALS IMPLICATIONS FOR DIFFERENTIAL TREATMENT OF THE LMD TUMOR
BIOM-03 THE ONCOGENIC FLIP IN PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE (LMD): LONGITUDINAL DETECTION IN CEREBROSPINAL FLUID TUMOR CELLS (CSF-TCS) REVEALS IMPLICATIONS FOR DIFFERENTIAL TREATMENT OF THE LMD TUMOR Open
INTRODUCTION Patients with LMD have poor prognosis and limited treatment options. Oncogene amplification of primary, metastatic, and CNS metastatic tumors can be heterogeneous. Therefore, patients with LMD may benefit from assessment of cl…
View article: Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics
Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics Open
These findings highlight the potential utility of molecular profiling of CSF as an early indicator of treatment response and an approach for identifying resistance mechanisms and optimal combination therapies.
View article: Longitudinal CSF Tumor Cell Enumeration and Mutational Analysis as a Driver for Leptomeningeal Disease Management
Longitudinal CSF Tumor Cell Enumeration and Mutational Analysis as a Driver for Leptomeningeal Disease Management Open
Background: Leptomeningeal disease (LMD) is challenging to diagnose and monitor given the poor sensitivity of current gold-standard diagnostics. Cerebrospinal fluid tumor cells (CSF-TCs) have been studied as a biomarker for disease managem…
View article: RMTD-08 RADIATION ABSORBED DOSE TO SPINAL CORD: THERAPY OF LEPTOMENINGEAL METASTASES USING BETA-EMISSION RADIOPHARMACEUTICALS
RMTD-08 RADIATION ABSORBED DOSE TO SPINAL CORD: THERAPY OF LEPTOMENINGEAL METASTASES USING BETA-EMISSION RADIOPHARMACEUTICALS Open
BACKGROUND Over 100,000 cancer patients develop leptomeningeal metastases (LM) annually in the US. LM prognosis is poor with limited treatment options. Beta-emission radiopharmaceuticals, for example, 186Re-nanoliposomes (Rhenium (186Re) O…
View article: BMRK-13 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123)
BMRK-13 CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123) Open
Leptomeningeal metastases (LM) in solid tumors is difficult to diagnose and treat, and occurs when there are cancer cells in the cerebrospinal fluid (CSF)/pia and arachnoid. Current standard of care methods to diagnose or assess treatment …
View article: OCTS-11 PHASE 1 DOSE ESCALATION OF RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): ONGOING CLINICAL STUDY UPDATE FOR INITIAL SAFETY AND FEASIBILITY
OCTS-11 PHASE 1 DOSE ESCALATION OF RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): ONGOING CLINICAL STUDY UPDATE FOR INITIAL SAFETY AND FEASIBILITY Open
BACKGROUND Leptomeningeal metastases (LM) is a devastating systemic cancer complication most often seen with breast, lung, renal cell, and melanoma, with limited treatment options and poor survival. Rhenium (186Re) Obisbemeda (186RNL) prov…
View article: BMRK-02 PROGNOSTIC VALUE OF CEREBROSPINAL FLUID TUMOR CELL COUNT IN LEPTOMENINGEAL DISEASE FROM SOLID TUMORS
BMRK-02 PROGNOSTIC VALUE OF CEREBROSPINAL FLUID TUMOR CELL COUNT IN LEPTOMENINGEAL DISEASE FROM SOLID TUMORS Open
Leptomeningeal disease (LMD) affects 5-10% of patients with solid tumors. Treatment decisions for LMD rely on patient risk stratification, since clinicians lack objective prognostic tools. The introduction of rare cell capture technology f…
View article: BMRK-12 THE CNSIDE CSF TUMOR CELL DETECTION PLATFORM IS A FEASIBLE, CLINICALLY RELEVANT AND SCALABLE PLATFORM FOR DISEASE MANAGEMENT FOR PATIENTS WITH LEPTOMENINGEAL DISEASE
BMRK-12 THE CNSIDE CSF TUMOR CELL DETECTION PLATFORM IS A FEASIBLE, CLINICALLY RELEVANT AND SCALABLE PLATFORM FOR DISEASE MANAGEMENT FOR PATIENTS WITH LEPTOMENINGEAL DISEASE Open
CNSide is a platform that analyzes Cerebrospinal Fluid (CSF) of patients with solid tumors having Leptomeningeal Disease for presence of tumor cells (CSF-TCs) and expression of different biomarkers via Fluorescent In Situ Hybridization (FI…
View article: A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients With Suspected Leptomeningeal Metastases
A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients With Suspected Leptomeningeal Metastases Open
Context.— Leptomeningeal disease (LMD) is a clinical sequela of central nervous system metastasis involving the cerebrospinal fluid (CSF), often seen in late-stage solid tumors. It has a grave prognosis without urgent treatment. Standard o…
View article: The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy
The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy Open
Introduction CNSide is a platform that detects and characterizes tumor cells in the cerebrospinal fluid (CSF) of patients with leptomeningeal disease (LMD). The platform was validated per College of American Pathologists (CAP) and Clinical…
View article: Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors
Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors Open
Purpose: Treatment decisions for leptomeningeal disease (LMD) rely on patient risk stratification, since clinicians lack objective prognostic tools. The introduction of rare cell capture technology for identification of cerebrospinal fluid…
View article: Keeping a track on leptomeningeal disease in non–small cell lung cancer: A single-institution experience with CNSideTM
Keeping a track on leptomeningeal disease in non–small cell lung cancer: A single-institution experience with CNSideTM Open
Background Leptomeningeal disease (LMD) is a devastating complication for patients with advanced cancer. Diagnosis and monitoring the response to therapy remains challenging due to limited sensitivity and specificity of standard-of-care (S…
View article: CTNI-02. A LONGITUDINAL THERAPY RESPONSE MONITORING STUDY IN SUBJECTS WITH LEPTOMENINGEAL METASTASES USING CNSIDE COMPARED TO STANDARD OF CARE (CSF CYTOLOGY, CLINICAL EVALUATION, IMAGING)
CTNI-02. A LONGITUDINAL THERAPY RESPONSE MONITORING STUDY IN SUBJECTS WITH LEPTOMENINGEAL METASTASES USING CNSIDE COMPARED TO STANDARD OF CARE (CSF CYTOLOGY, CLINICAL EVALUATION, IMAGING) Open
LM is diagnosed via clinical evaluation, neuroaxis neuroimaging (MRI brain and spine), and CSF cytology. These methods have limited sensitivity and specificity, and lack the ability to quantitatively measure the LM’s response to treatment.…
View article: SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY Open
INTRODUCTION Patients diagnosed with Leptomeningeal Metastasis (LM) have limited treatment options. However, they may benefit from targetable therapy. LM breast cancer patients with HER2 positive primary tumors treated with IT Trastuzumab …
View article: Investigating the contribution of hyaluronan to the breast tumour microenvironment using multiparametric <scp>MRI</scp> and <scp>MR</scp> elastography
Investigating the contribution of hyaluronan to the breast tumour microenvironment using multiparametric <span>MRI</span> and <span>MR</span> elastography Open
Hyaluronan (HA) is a key component of the dense extracellular matrix in breast cancer, and its accumulation is associated with poor prognosis and metastasis. Pegvorhyaluronidase alfa (PEGPH20) enzymatically degrades HA and can enhance drug…
View article: Figure S7 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Figure S7 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
Pegvorhyaluronidase alfa effect on density of T-cells and NK cells and proportion of Gr1+ myeloid-derived suppressor cells in EMT-6 orthotopic breast tumors
View article: Supplementary Data Combined from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Supplementary Data Combined from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
All supplementary data in one file
View article: Figure S3 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Figure S3 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
Pegvorhyaluronidase alfa increased density of T-cells and NK cells and decreased the proportion of Gr1+ myeloid-derived suppressor cells in 4T1/HAS3 orthotopic breast tumors
View article: Figure S4 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Figure S4 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression Open
AsPC-1 parental cells (AsPC-1-P) engineered to overexpress HAS3 (AsPC-1/HAS3, see Materials and Methods) produced more HA in the peritumoral matrix and the stroma.
View article: Figure S1 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Figure S1 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
Tumor growth in 4T1 and 4T1/HAS3 tumors
View article: Figure S3 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Figure S3 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression Open
Reduced tumor HA via enzymatic digestion decreases HIF-1α protein expression.
View article: Figure S2 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Figure S2 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression Open
PEGPH20-mediated HA degradation increases tumor vascular area and decreases tumor hypoxia in HA-accumulating tumors.
View article: Figure S4 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Figure S4 from Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression Open
AsPC-1 parental cells (AsPC-1-P) engineered to overexpress HAS3 (AsPC-1/HAS3, see Materials and Methods) produced more HA in the peritumoral matrix and the stroma.
View article: Supplementary Data from Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma
Supplementary Data from Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma Open
Supplementary figures 1-3
View article: Figure S4 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Figure S4 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
Pegvorhyaluronidase alfa increased density of T-cells and NK cells and decreased the proportion of Gr1+ myeloid-derived suppressor cells in 4T1/HAS3 orthotopic breast tumors
View article: Figure S2 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Figure S2 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
Immune cell composition in 4T1 and 4T1/HAS3 orthotopic breast tumors
View article: Figure S6 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Figure S6 from Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy Open
Pegvorhyaluronidase alfa in combination with anti-PD-L1 effect on density of T-cells and NK cells and the proportion of Gr1+ myeloid-derived suppressor cells in EMT-6 orthotopic breast tumors
View article: Data from Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer
Data from Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer Open
Purpose:Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells throug…